These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23001898)

  • 1. Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection.
    Bowen M; Armstrong N; Maa YF
    J Pharm Sci; 2012 Dec; 101(12):4433-43. PubMed ID: 23001898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
    Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spray-Dried Monoclonal Antibody Suspension for High-Concentration and Low-Viscosity Subcutaneous Injection.
    Huang C; Chen L; Franzen L; Anderski J; Qian F
    Mol Pharm; 2022 May; 19(5):1505-1514. PubMed ID: 35417176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Powder suspensions in non-aqueous vehicles for delivery of therapeutic proteins.
    Marschall C; Witt M; Hauptmeier B; Friess W
    Eur J Pharm Biopharm; 2021 Apr; 161():37-49. PubMed ID: 33548460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Product Characterization of High Concentration Non-Aqueous Protein Powder Suspensions.
    Marschall C; Witt M; Hauptmeier B; Frieß W
    J Pharm Sci; 2023 Jan; 112(1):61-75. PubMed ID: 35779665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of high concentration protein powder suspensions by milling of lyophilizates.
    Marschall C; Graf G; Witt M; Hauptmeier B; Friess W
    Eur J Pharm Biopharm; 2021 Sep; 166():75-86. PubMed ID: 34058328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls.
    Batens M; Massant J; Teodorescu B; Van den Mooter G
    Eur J Pharm Biopharm; 2018 Jun; 127():407-422. PubMed ID: 29499299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation the injectability of injectable microparticle delivery systems on the basis of injection force and discharged rate.
    Zhao C; Zhu Z; Cao X; Pan F; Li F; Xue M; Guo Y; Zhao Y; Zeng J; Liu Y; Yang Z; Liu Y; Ren F; Feng L
    Eur J Pharm Biopharm; 2023 Sep; 190():58-72. PubMed ID: 37437667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting shear thickening behavior of a concentrated injectable suspension of levodopa.
    Allahham A; Stewart P; Marriott J; Mainwaring D
    J Pharm Sci; 2005 Nov; 94(11):2393-402. PubMed ID: 16200618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures.
    Knepp VM; Muchnik A; Oldmark S; Kalashnikova L
    Pharm Res; 1998 Jul; 15(7):1090-5. PubMed ID: 9688065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral oil-based drospirenone microcrystal suspensions-evaluation of physicochemical stability and influence of stabilising agents.
    Nippe S; General S
    Int J Pharm; 2011 Sep; 416(1):181-8. PubMed ID: 21729745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization and dissolution performance of spray-dried naproxen nano-crystals.
    Kumar S; Shen J; Zolnik B; Sadrieh N; Burgess DJ
    Int J Pharm; 2015; 486(1-2):159-66. PubMed ID: 25814034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration.
    Dani B; Platz R; Tzannis ST
    J Pharm Sci; 2007 Jun; 96(6):1504-17. PubMed ID: 17387698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
    Shpilberg O; Jackisch C
    Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody.
    Deokar V; Sharma A; Mody R; Volety SM
    J Pharm Sci; 2020 Dec; 109(12):3579-3589. PubMed ID: 32946895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-scale screening method for low-viscosity antibody solutions using small-angle X-ray scattering.
    Fukuda M; Watanabe A; Hayasaka A; Muraoka M; Hori Y; Yamazaki T; Imaeda Y; Koga A
    Eur J Pharm Biopharm; 2017 Mar; 112():132-137. PubMed ID: 27890509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies.
    Wang S; Zhang N; Hu T; Dai W; Feng X; Zhang X; Qian F
    Mol Pharm; 2015 Dec; 12(12):4478-87. PubMed ID: 26528726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved tretinoin photostability in a topical nanomedicine replacing original liquid suspension with spray-dried powder with no loss of effectiveness.
    Marchiori MC; Rascovetzki RH; Ourique AF; Rigo LA; Silva CB; Beck RC
    Drug Dev Ind Pharm; 2013 Apr; 39(4):579-86. PubMed ID: 22697376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectability of high concentrated suspensions using model microparticles.
    Kowsari K; Lu L; Persak SC; Hu G; Forrest W; Berger R; Givand JC; Babaee S
    J Pharm Sci; 2024 Dec; 113(12):3525-3537. PubMed ID: 39369907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
    Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
    MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.